Straits Times Index
3,225.35 +23.46 (+0.73%) S&P 500
3,960.78 -128.07 (-3.13%) Dow
31,802.96 -851.63 (-2.61%) Nasdaq
11,532.82 -451.71 (-3.77%) BTC-USD
28,940.85 -1,068.29 (-3.56%) CMC Crypto 200
647.32 -23.36 (-3.48%)
Pfizer Inc. (PFE)
| Previous close | 51.34 |
| Open | 51.22 |
| Bid | 50.39 x 900 |
| Ask | 50.40 x 1200 |
| Day's range | 50.26 - 51.42 |
| 52-week range | 38.48 - 61.71 |
| Volume | |
| Avg. volume | 28,272,935 |
| Market cap | 283.575B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 13.11 |
| EPS (TTM) | 3.85 |
| Earnings date | 26 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | 1.60 (3.12%) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | 59.33 |
- Editor's pickYahoo Finance Video
Citi stock up after Berkshire discloses $3 billion stake, FDA approves Pfizer booster for ages 5-11
Citi shares popped after Berkshire Hathaway announced it had acquired 55 million shares of the company, the FDA approved Pfizer's COVID booster for ages 5-11, and JD.com topped Q1 sales estimates despite China lockdowns.
- Motley Fool
Why Pfizer Looks Better Than Moderna as a Long-Term Buy
For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.
- Zacks
Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
